| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8452777 | Experimental Hematology | 2017 | 16 Pages |
Abstract
- Prediabetes and diabetes represent adverse events in patients with chronic myeloid leukemia treated with nilotinib.
- An unweighted genetic risk score <10 predicts higher prediabetes/diabetes-free survival after nilotinib treatment.
- In clinical practice, the unweighted genetic risk score uGRS helps tailor the best tyrosine kinase inhibitor therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Bruno Martino, Corrado Mammì, Claudia Labate, Silvia Rodi, Domenica Ielo, Manuela Priolo, Maurizio Postorino, Giovanni Tripepi, Francesca Ronco, Carmelo Laganà , Caterina Musolino, Marianna Greco, Giorgio La Nasa, Giovanni Caocci,